baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Knock-Out AYJ/ DE000SU15AA3 /

2024-09-20 5:31:11 PM	Chg.+0.13	Bid10:00:36 PM	Ask10:00:36 PM	Underlying	Strike price	Expiration date	Option type
4.61EUR	+2.90%	- Bid Size: -	- Ask Size: -	VALNEVA SE EO...	7.1858 EUR	2078-12-31	Put

GlobeNewswire 09-03 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...

GlobeNewswire 08-13 Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

GlobeNewswire 08-01 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’...

GlobeNewswire 07-22 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the Wo...

GlobeNewswire 07-17 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...

GlobeNewswire 07-01 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ...

GlobeNewswire 06-26 Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Direct...

GlobeNewswire 06-24 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

GlobeNewswire 06-05 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...

GlobeNewswire 06-04 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

GlobeNewswire 06-03 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

GlobeNewswire 05-31 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

GlobeNewswire 05-21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

GlobeNewswire 05-13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...

GlobeNewswire 05-07 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire 03-26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

GlobeNewswire 03-25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

GlobeNewswire 03-21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...

GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

GlobeNewswire 03-18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...

GlobeNewswire 03-04 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

GlobeNewswire 02-29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...

GlobeNewswire 02-15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

GlobeNewswire 02-05 Valneva Announces Sale of Priority Review Voucher for $103 Million

GlobeNewswire 01-10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine

Soc. Generale Knock-Out AYJ/ DE000SU15AA3 /

If you wish to receive reply to your feedback, please provide your email address.